Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug HCA, CHS execs 'hopeful' deferred care will trickle back to hospitals in 2022 Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet Researchers uncover the brain's link to SIDS, setting up potential infant screening test Trial for controversial China-made Alzheimer’s drug aborted as capital raise hits snag, COVID hurts sales Crossover Health is opening health centers in new markets. Here's where the medical group is going next Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava Medtronic makes FTC-mandated sale to close Intersect ENT deal and scores FDA nod to boot Update: Checkmate details bleak future if $250M Regeneron merger does not close BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal Bristol Myers sells NY biologics plant for $160M to fuel Lotte's drugmaking ambitions Field Trip, Nue Life team up to expand psychedelic treatment into the home FDA clears BD's newest molecular diagnostics machine and its first test, a 3-in-one STI screener Featured Story | By Nick Paul Taylor That was fast. Just 39 hours after the bombshell failure of Roche’s TIGIT trial, iTeos Therapeutics revealed it and GlaxoSmithKline are assessing “how best to proceed with additional clinical development” of their rival asset in light of the phase 3 flop. read more |
| |
|---|
|
Top Stories By Dave Muoio Promising volume recovery in the months following omicron's surge has hospital chains cautiously optimistic about short-term consumer demand and flat out bullish for the years to come. read more By Angus Liu Despite an ongoing strategic review, Novartis' generics engine keeps churning out new products. Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis therapy Esbriet. read more By Conor Hale “This discovery changes the narrative around SIDS," said lead researcher Carmel Harrington, who lost her own child to sudden infant death syndrome 29 years ago. read more By Angus Liu A clinical trial for an Alzheimer’s disease drug approved in China that would otherwise have supported a potential FDA submission has stopped. read more By Heather Landi Crossover Health, a tech-enabled medical group, is expanding its national footprint of brick-and-mortar clinics and plans to open new health centers in Seattle and Austin. In an exclusive interview, Crossover's chief medical officer Stephen Ezeji-Okoye, M.D., shared with Fierce Healthcare how the company's model of care is different from other primary care players. read more By Kevin Dunleavy The FDA has approved an oral version of Mitsubishi Tanabe’s ALS drug Radicava, which can be taken at home and, if necessary, through a feeding tube. Radicava was initially approved in the U.S. in 2017, becoming the first new treatment for the condition in 22 years. read more By Andrea Park It may have taken an order from the FTC to get there, and Medtronic may be getting less bang for its buck than initially expected, but the medtech giant’s acquisition of Intersect ENT is finally complete. read more By Annalee Armstrong “Difficulties in employee retention.” “No assurance that we will be able to successfully raise sufficient additional capital.” “We may be forced to delay, reduce or eliminate some or all of our research and development programs.” This is the future facing Checkmate Pharmaceuticals if the $250 million Regeneron deal does not happen. read more By Annalee Armstrong A day after getting a nice fat—and sorely needed—paycheck from Bristol Myers, BridgeBio has sold off a priority review voucher, adding $110 million to its coffers. read more By Fraiser Kansteiner Under the deal, Lotte will continue to manufacture products for Bristol Myers from the plant as part of a “newly-established CDMO relationship” with the Big Pharma. Lotte is due to inherit the East Syracuse site’s operations and assets, including property, equipment and the plant’s workforce. read more By Anastassia Gliadkovskaya The companies hope their partnership to inspire more collaboration in the industry and improve the quality of the national conversation around psychedelics, which remain stigmatized. read more By Andrea Park When it comes to molecular diagnostics, BD is betting that three heads are better than one. read more |
